Atara Biotherapeutics (NASDAQ:ATRA) shares are trading higher on Wednesday on continued momentum from Tuesday after the FDA gave clearance of its IND for ATA2271.

Atara Biotherapeutics operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other viral diseases. The company achieves this through two groups of product candidates, such as allogenic or third-party derived antigen-specific T-cells and molecularly targeted biologics.

Atara Biotherapeutics shares were trading up 8.54% at $14.61 at the time of publication on Wednesday. The stock has a 52-week high of $19.36 and a 52-week low of $4.52.